Veterinary Medicines

Clavusan 250 mg + 62.5 mg tablets for dogs and cats

Authorised
  • Amoxicillin trihydrate
  • Potassium clavulanate
Download as PDF

Product identification

Medicine name:
Clavusan 250 mg + 62.5 mg tablets for dogs and cats
Clavusan 250 mg + 62.5 mg Comprimé
Clavusan 250 mg + 62.5 mg Tablet
Clavusan 250 mg + 62.5 mg Tablette
Active substance:
  • Amoxicillin trihydrate
  • Potassium clavulanate
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Amoxicillin trihydrate
    287.00
    milligram(s)
    /
    1.00
    Tablet
  • Potassium clavulanate
    74.45
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01CR02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes:Cardboard box of 250 tablets.
  • oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes:Cardboard box of 100 tablets.
  • oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes:Cardboard box of 50 tablets.
  • oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes:Cardboard box of 30 tablets.
  • oPA/Alu/PVC - PVC/Alu heat sealed blister containing 10 tablets each. Package sizes:Cardboard box of 10 tablets.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application – change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)
Marketing authorisation holder:
  • Alfasan Nederland B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
  • Alfasan Nederland B.V.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V661247
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0778/002
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 25/09/2024
Download
Dutch (PDF)
Published on: 12/06/2025
Download
French (PDF)
Published on: 12/06/2025
Download
German (PDF)
Published on: 12/06/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 12/06/2025
Download
French (PDF)
Published on: 12/06/2025
Download
German (PDF)
Published on: 12/06/2025
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 12/06/2025
Download
French (PDF)
Published on: 12/06/2025
Download
German (PDF)
Published on: 12/06/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."